Loading...
机构名称:
¥ 1.0

•治疗绝经后女性骨质疏松症的骨折高风险,被定义为骨质疏松骨折病史或骨折的多种危险因素;或失败或不容忍其他可用骨质疏松疗法的患者•增加骨质疏松症的男性骨骼质量高,骨质疏松症的骨量很高,被定义为骨质疏松性骨折的病史,或骨折的多种危险因素; or patients who have failed or are intolerant to other available osteoporosis therapy • Treatment of glucocorticoid-induced osteoporosis in men and women at high risk for fracture who are either initiating or continuing systemic glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and expected to remain on glucocorticoids for at least 6 months.高骨折的高风险被定义为骨质疏松性骨折的病史,骨折的多种危险因素或失败或对其他可用骨质疏松疗法不宽容的患者

denosumab-骨质疏松医学药物标准计划摘要

denosumab-骨质疏松医学药物标准计划摘要PDF文件第1页

denosumab-骨质疏松医学药物标准计划摘要PDF文件第2页

denosumab-骨质疏松医学药物标准计划摘要PDF文件第3页

denosumab-骨质疏松医学药物标准计划摘要PDF文件第4页

denosumab-骨质疏松医学药物标准计划摘要PDF文件第5页